Marshall Wace, LLP Phathom Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$8.97 - $12.05 $1.01 Million - $1.36 Million	112,691 New	112,691 $1.16 Million
Q1 2023 May 15, 2023	BUY	$6.19 - $12.36 $229,624 - $458,506	37,096 New	37,096 $264,000
Q2 2022 Aug 15, 2022	BUY	$6.2 - $15.5 $188,585 - $471,463	30,417 Added 124.91%	54,769 $462,000
Q1 2022 May 16, 2022	SELL	$11.55 - $20.06 $90,240 - $156,728	-7,813 Reduced 24.29%	24,352 $330,000
Q4 2021 Feb 14, 2022	BUY	$17.83 - $33.15 $43,398 - $80,687	2,434 Added 8.19%	32,165 $632,000
Q2 2021 Aug 13, 2021	SELL	$32.66 - $39.87 $2.75 Million - $3.36 Million	-84,154 Reduced 73.89%	29,731 $1.01 Million
Q1 2021 May 17, 2021	SELL	$33.86 - $48.68 $161,309 - $231,911	-4,764 Reduced 4.02%	113,885 $4.28 Million
Q4 2020 Feb 16, 2021	BUY	$33.22 - $50.26 $3.94 Million - $5.96 Million	118,649 New	118,649 $3.94 Million

144

73.6M

42.3K

45.7K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $292M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.